Skip to main content
Fig. 1 | BMC Dermatology

Fig. 1

From: Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial

Fig. 1

Patients using adalimumab, etanercept or ustekinumab will be randomized to dose tapering or usual care. Control visits will be planned every 3 months for the assessments of PASI, DLQI, cost-effectiveness questionnaires, drug levels and anti-drug antibodies (at trough moment). Ustekinumab blood samples for immunologic analyses are taken at deviating time points (trough moments) due to the low frequency of injections. CEQ = Cost-effectiveness questionnaires (SF-36, iMTA Medical Consumption Questionnaire and productivity cost questionnaire), PASI = Psoriasis Area and Severity Index, DLQI = Dermatology Quality of Life

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us